CA3058933A1 - Tesofensine pour la reduction du poids corporel chez des patients atteints du syndrome de prader-labhart-willi - Google Patents

Tesofensine pour la reduction du poids corporel chez des patients atteints du syndrome de prader-labhart-willi Download PDF

Info

Publication number
CA3058933A1
CA3058933A1 CA3058933A CA3058933A CA3058933A1 CA 3058933 A1 CA3058933 A1 CA 3058933A1 CA 3058933 A CA3058933 A CA 3058933A CA 3058933 A CA3058933 A CA 3058933A CA 3058933 A1 CA3058933 A1 CA 3058933A1
Authority
CA
Canada
Prior art keywords
tesofensine
metoprolol
beta
blocker
beta blocker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3058933A
Other languages
English (en)
Inventor
Jorgen Drejer
Thomas Amos JACOBSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saniona AS
Original Assignee
Saniona AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saniona AS filed Critical Saniona AS
Priority to CA3058933A priority Critical patent/CA3058933A1/fr
Priority to MX2021008208A priority patent/MX2021008208A/es
Priority to PCT/EP2020/050153 priority patent/WO2020144146A1/fr
Priority to US17/420,181 priority patent/US20220160658A1/en
Priority to BR112021013463-8A priority patent/BR112021013463A2/pt
Publication of CA3058933A1 publication Critical patent/CA3058933A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3058933A 2019-01-07 2019-10-16 Tesofensine pour la reduction du poids corporel chez des patients atteints du syndrome de prader-labhart-willi Pending CA3058933A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA3058933A CA3058933A1 (fr) 2019-10-16 2019-10-16 Tesofensine pour la reduction du poids corporel chez des patients atteints du syndrome de prader-labhart-willi
MX2021008208A MX2021008208A (es) 2019-01-07 2020-01-07 Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi.
PCT/EP2020/050153 WO2020144146A1 (fr) 2019-01-07 2020-01-07 Tesofensine pour la réduction du poids corporel chez des patients prader-willi
US17/420,181 US20220160658A1 (en) 2019-01-07 2020-01-07 Tesofensine for reduction of body weight in prader-willi patients
BR112021013463-8A BR112021013463A2 (pt) 2019-01-07 2020-01-07 Tesofensina para redução do peso corporal em pacientes com prader-willi

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA3058933A CA3058933A1 (fr) 2019-10-16 2019-10-16 Tesofensine pour la reduction du poids corporel chez des patients atteints du syndrome de prader-labhart-willi

Publications (1)

Publication Number Publication Date
CA3058933A1 true CA3058933A1 (fr) 2021-04-16

Family

ID=75492892

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3058933A Pending CA3058933A1 (fr) 2019-01-07 2019-10-16 Tesofensine pour la reduction du poids corporel chez des patients atteints du syndrome de prader-labhart-willi

Country Status (1)

Country Link
CA (1) CA3058933A1 (fr)

Similar Documents

Publication Publication Date Title
US11426383B2 (en) Tesofensine and beta blocker combination formulations
AU2006319411B8 (en) Neramexane modified release matrix tablet
AU2005298854B2 (en) Dosage form time-lagged of drugs for the therapy of insomnia
US20220160658A1 (en) Tesofensine for reduction of body weight in prader-willi patients
TW200814992A (en) Stabilized pharmaceutical compositions comprising fesoterodine
EP1507518B1 (fr) Association de formes posologiques de levodopa/carbidopa a liberation immediate et controlee
EP2802319B1 (fr) Polythérapie à base de doses fixes pour le traitement de la maladie de parkinson
CA3058933A1 (fr) Tesofensine pour la reduction du poids corporel chez des patients atteints du syndrome de prader-labhart-willi
US12016840B2 (en) Tesofensine and beta blocker combination formulations
CA3029052A1 (fr) Tesofensine pour la reduction du poids corporel chez des patients atteints du syndrome de prader-labhart-willi
EP4138830A1 (fr) Traitement de l'obésité hypothalamique
BR112017018871B1 (pt) Composição farmacêutica compreendendo metoprolol, tesofensina ou um sal farmaceuticamente aceitável dos mesmos